PROG - Progenity reports progress on drug delivery system

Progenity (NASDAQ:PROG) announced progress with its clinical device performance study plan, evaluating device function and safety of its drug delivery system (DDS) capsule. The company said its first clinical device performance study evaluated the safety and tolerability of its DDS capsule and validation of the device’s localization and delivery function in healthy volunteers. Progenity (PROG) said the DDS capsule was ingested orally and after localization, it released a saline solution payload that included radioisotopes. The DDS capsule was well tolerated and the study demonstrated the ability to accurately identify entry into the colon in 10 out of 12 people. The company noted that a clinical device performance study in patients with ulcerative colitis has begun recruiting.

For further details see:

Progenity reports progress on drug delivery system